Trials / Terminated
TerminatedNCT04952519
Efficacy of Amantadine Treatment in COVID-19 Patients
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 193 (actual)
- Sponsor
- Noblewell · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Demonstration of the efficacy of amantadine over placebo in the population of patients with moderate or severe COVID-19 in the initial stage of the disease treated in the hospital
Detailed description
Use of high-doses of amantadine in hospitalized patients in the early phase of moderate or severe COVID-19, compared to placebo, will shorten the duration of the disease and reduce the risk of death and treatment with invasive mechanical ventilation in Intensive Care Units (ICU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amantadine | Patients are treated with high doses of amantadine. |
Timeline
- Start date
- 2021-03-30
- Primary completion
- 2022-03-10
- Completion
- 2022-03-10
- First posted
- 2021-07-07
- Last updated
- 2022-09-30
Locations
12 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT04952519. Inclusion in this directory is not an endorsement.